Substance / Medication

Telotristat etiprate

Overview

Clinical overview including description, indications, and evidence base is pending physician authorship or FDA SPL integration. Graph-derived relationship data is available below.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Carcinoid Heart Disease: Prognostic Value of 5-Hydroxyindoleacetic Acid Levels and Impact on Survival: A Systematic Literature Review.
Buchanan-Hughes Amy, Pashley Alex, Feuilly Marion et al. · Neuroendocrinology · 2021
PMID: 32097914Meta-Analysis
Management of carcinoid syndrome: a systematic review and meta-analysis.
Hofland Johannes, Herrera-Martínez Aura D, Zandee Wouter T et al. · Endocr Relat Cancer · 2019
PMID: 30608900Meta-Analysis
Systemic Treatment Options for Carcinoid Syndrome: A Systematic Review.
Wolin Edward M, Benson Iii Al Bowen · Oncology · 2019
PMID: 31018209Meta-Analysis
Mega-dose intravenous octreotide for the treatment of carcinoid crisis: a systematic review.
Seymour Nicole, Sawh Sonja C · Can J Anaesth · 2013
PMID: 23328959Meta-Analysis
Telotristat Etiprate alleviates rheumatoid arthritis by targeting LGALS3 and affecting MAPK signaling.
Zhang Ling, Lin Yanwen, Xu Xinrui et al. · Intractable Rare Dis Res · 2023
PMID: 36873667OtherFull text (PMC)
Telotristat etiprate for carcinoid syndrome: a single-arm, multicenter trial.
Pavel Marianne, Hörsch Dieter, Caplin Martyn et al. · J Clin Endocrinol Metab · 2015
PMID: 25636046Trial
Blocking peripheral serotonin synthesis by telotristat etiprate (LX1032/LX1606) reduces severity of both chemical- and infection-induced intestinal inflammation.
Kim Janice J, Wang Huaqing, Terc Joshua D et al. · Am J Physiol Gastrointest Liver Physiol · 2015
PMID: 26206858Preclinical

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Telotristat etiprate (substance)
SNOMED CT
41129611000001104
UMLS CUI
C2825840

Clinical Data

This intervention maps to 1 entities in the Ltrl knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.